Claims for Patent: 6,780,610

Summary for Patent: 6,780,610

Title:	Identification of a smooth muscle cell (SMC) specific smooth muscle heavy chain (SM-MHC) promoter/enhancer
Abstract:	The present invention generally relates to promoters, enhancers and other regulatory elements of smooth muscle cells (\"SMC\"). The invention also generally relates to the use of these promoters, enhancers and other regulatory elements of SMC to create animal models to study SMC physiology and pathophysiology. The invention further relates to a smooth muscle myosin heavy chain (SM-MHC) promoter/enhancer element which is capable of conferring SMC-specific gene expression in vivo. The invention also relates to methods for the targeted knockout, or over-expression, of genes of interest within smooth muscle cells. The invention further relates to methods of conferring smooth muscle cell specific gene expression in vivo.
Inventor(s):	Owens; Gary K. (Earlysville, VA), Madsen; Cort (Robinsville, VA)
Assignee:	Setagon, Inc. (Charlottesville, VA)
Application Number:	09/600,319
Patent Claims:	1. A method of expressing a polynucleotide in a smooth muscle cell in vitro comprising, introducing into said smooth muscle cell said polynucleotide in operative association with a SM-MHC promoter/enhancer, wherein the SM-MHC promoter enhancer is selected from the group consisting of a polynucleotide comprising about +89 to about +11.7 kb with respect to the transcription start site of a rat myosin heavy chain gene; and a human SM-MHC promoter/enhancer, wherein the human promoter/enhancer comprises sufficient sequence from the first intron of the human SM MHC gene to confer SMC-specific expression in vivo. 2. An isolated SM-MHC promoter/enhancer comprising a portion of a rat myosin heavy chain gene wherein said promoter/enhancer is capable of conferring SMC specific expression in vivo and wherein the portion consists of a sequence from about -4.2 kb to about +11.7 kb with respect to the transcription start site of said rat myosin heavy chain gene. 3. An isolated SM-MHC promoter/enhancer comprising a portion of a rat myosin heavy chain gene wherein said promoter/enhancer is capable of conferring SMC specific expression in vivo and wherein the portion consists of a sequence from about +1 kb to about +11.7 kb with respect to the transcription start site of said rat myosin heavy chain gene. 4. The SM-MHC promoter/enhancer of claim 3, wherein said portion consists of a sequence from about +89 to about +11.7 kb with respect to the transcription start site of said rat myosin heavy chain gene. 5. An isolated polynucleotide comprising a human SM-MHC promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the human SM MHC gene to confer SMC-specific expression in vivo. 6. The isolated polynucleotide of claim 5, wherein the promoter/enhancer further comprises a CArG1, CArG2, CArG3 and GC Repressor sequence. 7. A vector comprising the polynucleotide of claim 5. 8. An isolated cell comprising the vector of claim 7.

Details for Patent 6,780,610

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-01-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-01-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-01-16